ASP Isotopes Inc. (NASDAQ: ASPI) has provided a comprehensive business update, including significant developments in its supply agreements and strategic acquisitions. The company has entered into a supply contract with a U.S.-based customer for enriched silicon-28, representing its largest silicon-28 contract to date. Deliveries are expected during Q1 2026. The acquisition of an independent radiopharmacy in Florida, United States, aligns with the company's strategy to expand its nuclear medicine business, especially the operations of its subsidiary, Pet Labs Pharmaceuticals (Pty) Ltd, in South Africa.
The supply contract for enriched silicon-28 underlines the company’s progress in its electronic gases strategy. Enriched silicon-28 is a crucial material for solid-state quantum computing and advanced semiconductor architectures. This material advantage is pivotal in building scalable, fault-tolerant quantum processors. The global investment in quantum computing and advanced electronics has led to growing demand for high-purity silicon-28, positioning ASP Isotopes as a key supplier in this dynamic sector.
The acquisition of the radiopharmacy in Florida is expected to be accretive to the company's 2026 revenues, EBITDA, and EPS. This strategic move complements and expands the operations of Pet Labs and represents its first expansion outside South Africa. The company expects to start offering positron emission tomography (PET) services from 2027 onwards, which is projected to contribute to future revenue and profit growth.
Furthermore, Pet Labs is aiming to build a vertically integrated radiopharmacy network in the United States, with plans for additional acquisitions and discussions with multiple independent radiopharmacies in various jurisdictions. This expansion strategy is designed to meet the increasing demand for radiodiagnostics and radiotherapeutics, with the ultimate goal of establishing Pet Labs as a global leader in the production of radioisotopes for treating various forms of oncology.
The company’s CEO, Dr. Gerdus Kemp, highlighted the significance of this acquisition as the first step in Pet Labs' planned expansion outside South Africa. The company aims to achieve global leadership in the production of radioisotopes to address numerous forms of oncology. Additionally, Pet Labs plans to present its growth strategy and provide detailed information on its biotechnology assets during an upcoming investor access event in November 2025.
In terms of personnel developments, a new non-executive employee of ASP Isotopes Inc. was granted an award of restricted stock as an employment inducement award in accordance with NASDAQ listing rules.
ASP Isotopes Inc. is an advanced materials company dedicated to developing technology and processes for producing isotopes across multiple industries. The company’s proprietary technology, the Aerodynamic Separation Process (ASP Technology), is employed for isotope production. With a growing demand for isotopes such as silicon-28, molybdenum-100, molybdenum-98, zinc-68, ytterbium-176, and nickel-64 in emerging healthcare applications, as well as for green energy applications, ASP Isotopes Inc. is well-positioned to cater to these evolving market needs. As a result of these announcements, the company's shares have moved 31.49% on the market, and are now trading at a price of $13.32. For more information, read the company's full 8-K submission here.
